CA
NZ
UK
AU
IND
US
…
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Cybin Inc. is a biotechnology company focused on developing psychedelic-based therapeutics and proprietary formulation and delivery technologies intended to treat psychiatric and neurological disorders. Long-term growth drivers may include greater clinical validation of psychedelic-assisted therapies, potential regulatory acceptance, and successful commercialization of differentiated delivery platforms. Investors may find the company attractive because successful clinical progress could create significant upside from early-stage therapeutic programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Income before tax | -57.69M | -113.61M | -78.08M | -47.74M | -67.80M |
| Net income | -147.05M | -113.14M | -78.08M | -47.49M | -67.63M |
| Selling general administrative | 49.55M | 84.95M | 27.90M | 25.15M | 44.79M |
| Selling and marketing expenses | 6.45M | 3.29M | 18.57M | 0.88M | 1.47M |
| Gross profit | -44.80M | -0.47M | -18.57M | -0.25M | -0.17M |
| Reconciled depreciation | 0.12M | 0.47M | 0.42M | 0.25M | 0.17M |
| Ebit | -141.68M | -143.15M | -78.84M | -51.52M | -63.84M |
| Ebitda | -141.56M | -142.94M | -78.41M | -51.27M | -63.67M |
| Depreciation and amortization | 0.12M | 0.21M | 0.42M | 0.25M | 0.17M |
| Operating income | -141.68M | -143.15M | -78.84M | -51.52M | -63.84M |
| Other operating expenses | 96.99M | 143.62M | 78.84M | 51.77M | 64.01M |
| Interest expense | 4.04M | - | - | - | 0.24M |
| Interest income | 5.10M | 8.29M | 0.62M | 0.60M | 0.24M |
| Net interest income | 2.18M | 8.29M | 0.62M | 0.60M | 0.24M |
| Income tax expense | 89.37M | -0.47M | 36.72M | -0.25M | -0.17M |
| Total revenue | -44.68M | 0.47M | -18.15M | 0.25M | 0.17M |
| Total operating expenses | 96.87M | 143.15M | 78.84M | 51.52M | 63.84M |
| Cost of revenue | 0.12M | 0.47M | 0.42M | 0.25M | 0.17M |
| Total other income expense net | 83.99M | 29.54M | 0.76M | 3.78M | -3.96M |
| Net income from continuing ops | -148.00M | -113.14M | -78.08M | -47.49M | -67.63M |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Total assets | 251.98M | 258.62M | 302.02M | 53.90M | 84.06M |
| Intangible assets | 30.32M | 41.02M | 35.47M | 5.47M | 2.08M |
| Other current assets | 22.31M | 25.07M | 5.07M | 3.50M | 2.61M |
| Total liab | 19.44M | 21.42M | 10.10M | 5.66M | 7.91M |
| Total stockholder equity | 232.24M | 237.20M | 291.93M | 48.23M | 76.16M |
| Other current liab | 19.44M | - | -0.29M | 2.25M | 2.65M |
| Common stock | 493.72M | 464.36M | 443.88M | 158.16M | 141.45M |
| Capital stock | 492.10M | 464.36M | 443.88M | 158.16M | 141.45M |
| Retained earnings | -390.82M | -339.37M | -226.23M | -148.15M | -100.66M |
| Good will | 36.34M | 51.49M | 47.48M | 24.79M | 22.89M |
| Cash | 157.78M | 135.02M | 208.99M | 16.63M | 53.64M |
| Total current liabilities | 19.44M | 21.42M | 10.10M | 5.66M | 7.91M |
| Net debt | -157.78M | -135.02M | -208.70M | -16.63M | -53.64M |
| Short term debt | - | - | 0.29M | - | - |
| Short long term debt total | - | - | 0.29M | - | - |
| Other stockholder equity | 121.25M | 119.44M | 76.57M | 40.26M | 35.73M |
| Total current assets | 185.11M | 165.97M | 218.54M | 23.18M | 58.35M |
| Long term investments | - | - | - | 0.00M | 0.24M |
| Net receivables | 5.03M | 5.88M | 4.48M | 3.05M | 2.10M |
| Inventory | - | - | - | 1.27M | -0.21M |
| Accounts payable | - | 21.42M | 9.80M | 5.66M | 5.26M |
| Accumulated other comprehensive income | 8.08M | -7.23M | -2.29M | -2.04M | -0.37M |
| Non currrent assets other | - | - | - | 5.00M | -0.24M |
| Non current assets total | 66.86M | 92.65M | 83.49M | 30.71M | 25.71M |
| Capital lease obligations | - | 0.00M | 0.29M | - | - |
| Breakdown | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
| Investments | - | - | - | 0.00M | -0.25M |
| Total cashflows from investing activities | -1.35M | -1.97M | 6.92M | -3.31M | -0.77M |
| Net borrowings | 24.35M | -0.29M | -0.15M | 0.00M | - |
| Total cash from financing activities | 196.97M | 20.20M | 254.51M | 13.56M | 35.78M |
| Net income | -147.05M | -113.14M | -78.08M | -47.49M | -67.63M |
| Change in cash | 63.96M | -73.97M | 192.36M | -37.01M | -10.38M |
| Begin period cash flow | 93.82M | 208.99M | 16.63M | 53.64M | 64.03M |
| End period cash flow | 157.78M | 135.02M | 208.99M | 16.63M | 53.64M |
| Total cash from operating activities | -132.42M | -101.30M | -68.91M | -47.43M | -45.21M |
| Issuance of capital stock | 146.05M | 20.49M | 254.60M | 13.20M | 31.51M |
| Depreciation | 0.12M | 0.47M | 0.42M | 0.25M | 0.17M |
| Other cashflows from investing activities | - | - | -0.71M | -3.17M | -0.41M |
| Change to inventory | - | - | - | - | -0.51M |
| Change to account receivables | -0.93M | -1.41M | -1.09M | -0.95M | -0.77M |
| Other cashflows from financing activities | - | - | 0.06M | 0.36M | 0.05M |
| Capital expenditures | 1.36M | 1.97M | 0.71M | 3.31M | 0.52M |
| Change in working capital | -1.25M | -9.79M | -5.03M | -1.44M | 0.21M |
| Stock based compensation | 10.86M | 42.87M | 13.89M | 4.69M | 18.03M |
| Other non cash items | 15.76M | -21.71M | -0.11M | -3.44M | 4.01M |
| Free cash flow | -133.79M | -103.27M | -69.62M | -50.74M | -45.73M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| HELP Cybin Inc. |
-0.12 1.07% |
10.60 | - | - | 16436.36 | 4.11 | 11762.75 |
| NVO Novo Nordisk A/S |
0.86 2.20% |
40.00 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 |
| VRTX Vertex Pharmaceuticals Inc |
18.88 3.50% |
558.88 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 |
| REGN Regeneron Pharmaceuticals Inc |
109.12 13.33% |
927.89 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 |
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
| Name | Title | Year Born |
|---|---|---|
| Mr. Eric So L.L.B. | Co-Founder, President & Executive Chairman | 1976 |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director | 1989 |
| Mr. Greg Cavers | Chief Financial Officer | 1971 |
| Mr. Aaron Bartlone | Chief Operating Officer | 1967 |
| Dr. Amir Inamdar FFPM, MBBS | Chief Medical Officer | 1974 |
| Mr. Michael I. Halstead J.D. | Chief Executive Officer | 1973 |
| Mr. John Kanakis | Co-Founder | 1980 |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer | 1960 |
| Ms. Lori Challenger | Chief Compliance, Ethics & Administrative Officer | NA |
| Mr. Gabriel Fahel | Chief Legal Officer & Corporate Secretary | 1976 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...